nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—ALB—Vandetanib—thyroid cancer	0.141	0.504	CbGbCtD
Captopril—ABCB1—Sorafenib—thyroid cancer	0.0446	0.159	CbGbCtD
Captopril—CYP2D6—Sorafenib—thyroid cancer	0.042	0.15	CbGbCtD
Captopril—ABCB1—Doxorubicin—thyroid cancer	0.0271	0.0964	CbGbCtD
Captopril—CYP2D6—Doxorubicin—thyroid cancer	0.0255	0.0908	CbGbCtD
Captopril—LTA4H—saliva-secreting gland—thyroid cancer	0.0125	0.0801	CbGeAlD
Captopril—REN—neck—thyroid cancer	0.0124	0.0793	CbGeAlD
Captopril—MMP2—neck—thyroid cancer	0.0114	0.0729	CbGeAlD
Captopril—MMP9—neck—thyroid cancer	0.00991	0.0634	CbGeAlD
Captopril—REN—saliva-secreting gland—thyroid cancer	0.00967	0.0618	CbGeAlD
Captopril—LTA4H—trachea—thyroid cancer	0.00966	0.0618	CbGeAlD
Captopril—MMP2—saliva-secreting gland—thyroid cancer	0.00889	0.0568	CbGeAlD
Captopril—F2—neck—thyroid cancer	0.00865	0.0553	CbGeAlD
Captopril—LTA4H—thyroid gland—thyroid cancer	0.00764	0.0489	CbGeAlD
Captopril—MMP2—trachea—thyroid cancer	0.00686	0.0438	CbGeAlD
Captopril—LTA4H—head—thyroid cancer	0.00678	0.0434	CbGeAlD
Captopril—MMP2—thyroid gland—thyroid cancer	0.00542	0.0347	CbGeAlD
Captopril—ACE—neck—thyroid cancer	0.00528	0.0338	CbGeAlD
Captopril—REN—head—thyroid cancer	0.00523	0.0335	CbGeAlD
Captopril—MMP2—head—thyroid cancer	0.00481	0.0308	CbGeAlD
Captopril—LTA4H—lymph node—thyroid cancer	0.00475	0.0304	CbGeAlD
Captopril—MMP9—head—thyroid cancer	0.00418	0.0268	CbGeAlD
Captopril—F2—head—thyroid cancer	0.00365	0.0233	CbGeAlD
Captopril—MMP2—lymph node—thyroid cancer	0.00337	0.0215	CbGeAlD
Captopril—MMP9—lymph node—thyroid cancer	0.00293	0.0187	CbGeAlD
Captopril—ACE—thyroid gland—thyroid cancer	0.00251	0.0161	CbGeAlD
Captopril—ACE—head—thyroid cancer	0.00223	0.0143	CbGeAlD
Captopril—Erythema multiforme—Vandetanib—thyroid cancer	0.00211	0.00647	CcSEcCtD
Captopril—Alopecia—Vandetanib—thyroid cancer	0.00197	0.00604	CcSEcCtD
Captopril—Dysgeusia—Vandetanib—thyroid cancer	0.0019	0.00583	CcSEcCtD
Captopril—Pancreatitis—Sorafenib—thyroid cancer	0.00184	0.00565	CcSEcCtD
Captopril—Vision blurred—Vandetanib—thyroid cancer	0.00183	0.00561	CcSEcCtD
Captopril—Myasthenia—Epirubicin—thyroid cancer	0.00176	0.0054	CcSEcCtD
Captopril—Neutropenia—Sorafenib—thyroid cancer	0.00176	0.00539	CcSEcCtD
Captopril—Erectile dysfunction—Sorafenib—thyroid cancer	0.00173	0.00531	CcSEcCtD
Captopril—Loss of consciousness—Vandetanib—thyroid cancer	0.0017	0.00523	CcSEcCtD
Captopril—Weight decreased—Sorafenib—thyroid cancer	0.0017	0.00522	CcSEcCtD
Captopril—Cough—Vandetanib—thyroid cancer	0.00169	0.0052	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00166	0.0051	CcSEcCtD
Captopril—Arthralgia—Vandetanib—thyroid cancer	0.00165	0.00507	CcSEcCtD
Captopril—Chest pain—Vandetanib—thyroid cancer	0.00165	0.00507	CcSEcCtD
Captopril—Renal failure—Sorafenib—thyroid cancer	0.00165	0.00505	CcSEcCtD
Captopril—ALB—lymph node—thyroid cancer	0.00163	0.0104	CbGeAlD
Captopril—Stomatitis—Sorafenib—thyroid cancer	0.00163	0.00501	CcSEcCtD
Captopril—Jaundice—Sorafenib—thyroid cancer	0.00163	0.00501	CcSEcCtD
Captopril—Myasthenia—Doxorubicin—thyroid cancer	0.00163	0.005	CcSEcCtD
Captopril—Dry mouth—Vandetanib—thyroid cancer	0.00161	0.00496	CcSEcCtD
Captopril—ACE—lymph node—thyroid cancer	0.00156	0.00999	CbGeAlD
Captopril—Thrombocytopenia—Vandetanib—thyroid cancer	0.00155	0.00476	CcSEcCtD
Captopril—Blister—Epirubicin—thyroid cancer	0.00153	0.00471	CcSEcCtD
Captopril—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00144	0.00443	CcSEcCtD
Captopril—Insomnia—Vandetanib—thyroid cancer	0.00143	0.0044	CcSEcCtD
Captopril—Paraesthesia—Vandetanib—thyroid cancer	0.00142	0.00436	CcSEcCtD
Captopril—Erythema multiforme—Sorafenib—thyroid cancer	0.00142	0.00436	CcSEcCtD
Captopril—Blister—Doxorubicin—thyroid cancer	0.00142	0.00436	CcSEcCtD
Captopril—Dyspnoea—Vandetanib—thyroid cancer	0.00141	0.00433	CcSEcCtD
Captopril—Necrosis—Epirubicin—thyroid cancer	0.00141	0.00433	CcSEcCtD
Captopril—Flushing—Sorafenib—thyroid cancer	0.00139	0.00428	CcSEcCtD
Captopril—Dyspepsia—Vandetanib—thyroid cancer	0.00139	0.00428	CcSEcCtD
Captopril—Decreased appetite—Vandetanib—thyroid cancer	0.00138	0.00422	CcSEcCtD
Captopril—Ageusia—Epirubicin—thyroid cancer	0.00136	0.00419	CcSEcCtD
Captopril—Fatigue—Vandetanib—thyroid cancer	0.00136	0.00419	CcSEcCtD
Captopril—Constipation—Vandetanib—thyroid cancer	0.00135	0.00416	CcSEcCtD
Captopril—Alopecia—Sorafenib—thyroid cancer	0.00133	0.00408	CcSEcCtD
Captopril—Liver injury—Epirubicin—thyroid cancer	0.00131	0.00404	CcSEcCtD
Captopril—Necrosis—Doxorubicin—thyroid cancer	0.0013	0.004	CcSEcCtD
Captopril—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00129	0.00397	CcSEcCtD
Captopril—Dysgeusia—Sorafenib—thyroid cancer	0.00128	0.00393	CcSEcCtD
Captopril—Ageusia—Doxorubicin—thyroid cancer	0.00126	0.00388	CcSEcCtD
Captopril—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00126	0.00386	CcSEcCtD
Captopril—Abdominal pain—Vandetanib—thyroid cancer	0.00125	0.00384	CcSEcCtD
Captopril—Body temperature increased—Vandetanib—thyroid cancer	0.00125	0.00384	CcSEcCtD
Captopril—Liver injury—Doxorubicin—thyroid cancer	0.00122	0.00373	CcSEcCtD
Captopril—Anaemia—Sorafenib—thyroid cancer	0.00121	0.00371	CcSEcCtD
Captopril—Oliguria—Epirubicin—thyroid cancer	0.0012	0.00368	CcSEcCtD
Captopril—Glossitis—Epirubicin—thyroid cancer	0.0012	0.00368	CcSEcCtD
Captopril—Angioedema—Sorafenib—thyroid cancer	0.0012	0.00367	CcSEcCtD
Captopril—Syncope—Sorafenib—thyroid cancer	0.00117	0.0036	CcSEcCtD
Captopril—Ulcer—Epirubicin—thyroid cancer	0.00117	0.00359	CcSEcCtD
Captopril—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00116	0.00358	CcSEcCtD
Captopril—Loss of consciousness—Sorafenib—thyroid cancer	0.00115	0.00353	CcSEcCtD
Captopril—Cough—Sorafenib—thyroid cancer	0.00114	0.00351	CcSEcCtD
Captopril—Asthenia—Vandetanib—thyroid cancer	0.00114	0.00349	CcSEcCtD
Captopril—Pruritus—Vandetanib—thyroid cancer	0.00112	0.00344	CcSEcCtD
Captopril—ABCB1—trachea—thyroid cancer	0.00112	0.00715	CbGeAlD
Captopril—Myalgia—Sorafenib—thyroid cancer	0.00111	0.00342	CcSEcCtD
Captopril—Arthralgia—Sorafenib—thyroid cancer	0.00111	0.00342	CcSEcCtD
Captopril—Glossitis—Doxorubicin—thyroid cancer	0.00111	0.00341	CcSEcCtD
Captopril—Oliguria—Doxorubicin—thyroid cancer	0.00111	0.00341	CcSEcCtD
Captopril—Hepatocellular injury—Epirubicin—thyroid cancer	0.00111	0.0034	CcSEcCtD
Captopril—CYP2D6—head—thyroid cancer	0.00109	0.00698	CbGeAlD
Captopril—Dry mouth—Sorafenib—thyroid cancer	0.00109	0.00334	CcSEcCtD
Captopril—Hyperkalaemia—Epirubicin—thyroid cancer	0.00109	0.00334	CcSEcCtD
Captopril—Diarrhoea—Vandetanib—thyroid cancer	0.00108	0.00333	CcSEcCtD
Captopril—Ulcer—Doxorubicin—thyroid cancer	0.00108	0.00332	CcSEcCtD
Captopril—Anaphylactic shock—Sorafenib—thyroid cancer	0.00107	0.00328	CcSEcCtD
Captopril—Shock—Sorafenib—thyroid cancer	0.00105	0.00323	CcSEcCtD
Captopril—Dizziness—Vandetanib—thyroid cancer	0.00105	0.00321	CcSEcCtD
Captopril—Thrombocytopenia—Sorafenib—thyroid cancer	0.00105	0.00321	CcSEcCtD
Captopril—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00102	0.00314	CcSEcCtD
Captopril—Dry eye—Epirubicin—thyroid cancer	0.00102	0.00314	CcSEcCtD
Captopril—Anorexia—Sorafenib—thyroid cancer	0.00102	0.00312	CcSEcCtD
Captopril—Vomiting—Vandetanib—thyroid cancer	0.00101	0.00309	CcSEcCtD
Captopril—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00101	0.00309	CcSEcCtD
Captopril—Rash—Vandetanib—thyroid cancer	0.000998	0.00306	CcSEcCtD
Captopril—Dermatitis—Vandetanib—thyroid cancer	0.000997	0.00306	CcSEcCtD
Captopril—Headache—Vandetanib—thyroid cancer	0.000991	0.00304	CcSEcCtD
Captopril—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000973	0.00299	CcSEcCtD
Captopril—Dyspnoea—Sorafenib—thyroid cancer	0.000952	0.00292	CcSEcCtD
Captopril—Dry eye—Doxorubicin—thyroid cancer	0.000945	0.0029	CcSEcCtD
Captopril—Lymphadenopathy—Epirubicin—thyroid cancer	0.000941	0.00289	CcSEcCtD
Captopril—Nausea—Vandetanib—thyroid cancer	0.00094	0.00289	CcSEcCtD
Captopril—Dyspepsia—Sorafenib—thyroid cancer	0.00094	0.00289	CcSEcCtD
Captopril—Decreased appetite—Sorafenib—thyroid cancer	0.000928	0.00285	CcSEcCtD
Captopril—Diabetes mellitus—Epirubicin—thyroid cancer	0.000923	0.00283	CcSEcCtD
Captopril—Fatigue—Sorafenib—thyroid cancer	0.00092	0.00283	CcSEcCtD
Captopril—Photosensitivity—Epirubicin—thyroid cancer	0.000914	0.00281	CcSEcCtD
Captopril—Constipation—Sorafenib—thyroid cancer	0.000913	0.0028	CcSEcCtD
Captopril—ABCB1—thyroid gland—thyroid cancer	0.000885	0.00566	CbGeAlD
Captopril—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000873	0.00268	CcSEcCtD
Captopril—Lymphadenopathy—Doxorubicin—thyroid cancer	0.00087	0.00267	CcSEcCtD
Captopril—Renal failure acute—Epirubicin—thyroid cancer	0.000869	0.00267	CcSEcCtD
Captopril—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000854	0.00262	CcSEcCtD
Captopril—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000851	0.00261	CcSEcCtD
Captopril—Photosensitivity—Doxorubicin—thyroid cancer	0.000846	0.0026	CcSEcCtD
Captopril—Abdominal pain—Sorafenib—thyroid cancer	0.000844	0.00259	CcSEcCtD
Captopril—Body temperature increased—Sorafenib—thyroid cancer	0.000844	0.00259	CcSEcCtD
Captopril—Dermatitis bullous—Epirubicin—thyroid cancer	0.00084	0.00258	CcSEcCtD
Captopril—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000829	0.00255	CcSEcCtD
Captopril—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000819	0.00252	CcSEcCtD
Captopril—Hyponatraemia—Epirubicin—thyroid cancer	0.000806	0.00247	CcSEcCtD
Captopril—Renal failure acute—Doxorubicin—thyroid cancer	0.000804	0.00247	CcSEcCtD
Captopril—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000787	0.00242	CcSEcCtD
Captopril—ABCB1—head—thyroid cancer	0.000785	0.00502	CbGeAlD
Captopril—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000777	0.00239	CcSEcCtD
Captopril—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000767	0.00236	CcSEcCtD
Captopril—Asthenia—Sorafenib—thyroid cancer	0.000766	0.00235	CcSEcCtD
Captopril—Cardiac arrest—Epirubicin—thyroid cancer	0.000763	0.00234	CcSEcCtD
Captopril—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000758	0.00233	CcSEcCtD
Captopril—Pruritus—Sorafenib—thyroid cancer	0.000755	0.00232	CcSEcCtD
Captopril—Ataxia—Epirubicin—thyroid cancer	0.000755	0.00232	CcSEcCtD
Captopril—Hyponatraemia—Doxorubicin—thyroid cancer	0.000746	0.00229	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—NRG1—thyroid cancer	0.000737	0.0031	CbGpPWpGaD
Captopril—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000733	0.00225	CcSEcCtD
Captopril—LTA4H—Metabolism—TPR—thyroid cancer	0.000732	0.00308	CbGpPWpGaD
Captopril—Diarrhoea—Sorafenib—thyroid cancer	0.00073	0.00224	CcSEcCtD
Captopril—LTA4H—Metabolism—PRKAR1A—thyroid cancer	0.00072	0.00303	CbGpPWpGaD
Captopril—MMP2—Axon guidance—CDK1—thyroid cancer	0.000719	0.00303	CbGpPWpGaD
Captopril—Muscular weakness—Epirubicin—thyroid cancer	0.000708	0.00217	CcSEcCtD
Captopril—Cardiac arrest—Doxorubicin—thyroid cancer	0.000706	0.00217	CcSEcCtD
Captopril—Dizziness—Sorafenib—thyroid cancer	0.000706	0.00217	CcSEcCtD
Captopril—Ataxia—Doxorubicin—thyroid cancer	0.000698	0.00214	CcSEcCtD
Captopril—MMP2—LPA receptor mediated events—HRAS—thyroid cancer	0.000691	0.00291	CbGpPWpGaD
Captopril—Eosinophilia—Epirubicin—thyroid cancer	0.000687	0.00211	CcSEcCtD
Captopril—Pancreatitis—Epirubicin—thyroid cancer	0.00068	0.00209	CcSEcCtD
Captopril—Vomiting—Sorafenib—thyroid cancer	0.000679	0.00208	CcSEcCtD
Captopril—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000678	0.00208	CcSEcCtD
Captopril—Angina pectoris—Epirubicin—thyroid cancer	0.000676	0.00208	CcSEcCtD
Captopril—Rash—Sorafenib—thyroid cancer	0.000673	0.00207	CcSEcCtD
Captopril—Dermatitis—Sorafenib—thyroid cancer	0.000672	0.00207	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—CCND1—thyroid cancer	0.00067	0.00282	CbGpPWpGaD
Captopril—Headache—Sorafenib—thyroid cancer	0.000669	0.00205	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000668	0.00281	CbGpPWpGaD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000665	0.0028	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000659	0.00278	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000659	0.00278	CbGpPWpGaD
Captopril—Pancytopenia—Epirubicin—thyroid cancer	0.000659	0.00202	CcSEcCtD
Captopril—Muscular weakness—Doxorubicin—thyroid cancer	0.000655	0.00201	CcSEcCtD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000653	0.00275	CbGpPWpGaD
Captopril—Neutropenia—Epirubicin—thyroid cancer	0.000649	0.00199	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000647	0.00273	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—PTEN—thyroid cancer	0.000646	0.00272	CbGpPWpGaD
Captopril—F2—Peptide ligand-binding receptors—SST—thyroid cancer	0.000641	0.0027	CbGpPWpGaD
Captopril—Pollakiuria—Epirubicin—thyroid cancer	0.000641	0.00197	CcSEcCtD
Captopril—Eosinophilia—Doxorubicin—thyroid cancer	0.000636	0.00195	CcSEcCtD
Captopril—Nausea—Sorafenib—thyroid cancer	0.000634	0.00195	CcSEcCtD
Captopril—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000633	0.00194	CcSEcCtD
Captopril—Pancreatitis—Doxorubicin—thyroid cancer	0.000629	0.00193	CcSEcCtD
Captopril—Weight decreased—Epirubicin—thyroid cancer	0.000628	0.00193	CcSEcCtD
Captopril—Angina pectoris—Doxorubicin—thyroid cancer	0.000625	0.00192	CcSEcCtD
Captopril—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000623	0.00262	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000613	0.00188	CcSEcCtD
Captopril—MMP2—LPA receptor mediated events—AKT1—thyroid cancer	0.00061	0.00257	CbGpPWpGaD
Captopril—Pancytopenia—Doxorubicin—thyroid cancer	0.00061	0.00187	CcSEcCtD
Captopril—Renal failure—Epirubicin—thyroid cancer	0.000608	0.00187	CcSEcCtD
Captopril—Jaundice—Epirubicin—thyroid cancer	0.000603	0.00185	CcSEcCtD
Captopril—Stomatitis—Epirubicin—thyroid cancer	0.000603	0.00185	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000602	0.00254	CbGpPWpGaD
Captopril—Neutropenia—Doxorubicin—thyroid cancer	0.0006	0.00184	CcSEcCtD
Captopril—MMP2—AGE/RAGE pathway—AKT1—thyroid cancer	0.000595	0.00251	CbGpPWpGaD
Captopril—Pollakiuria—Doxorubicin—thyroid cancer	0.000593	0.00182	CcSEcCtD
Captopril—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000586	0.0018	CcSEcCtD
Captopril—Weight decreased—Doxorubicin—thyroid cancer	0.000581	0.00178	CcSEcCtD
Captopril—Agranulocytosis—Epirubicin—thyroid cancer	0.000577	0.00177	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000572	0.00241	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000567	0.00174	CcSEcCtD
Captopril—MMP2—Direct p53 effectors—PTEN—thyroid cancer	0.000566	0.00238	CbGpPWpGaD
Captopril—Renal failure—Doxorubicin—thyroid cancer	0.000563	0.00173	CcSEcCtD
Captopril—MMP9—TWEAK Signaling Pathway—AKT1—thyroid cancer	0.000561	0.00236	CbGpPWpGaD
Captopril—Stomatitis—Doxorubicin—thyroid cancer	0.000558	0.00171	CcSEcCtD
Captopril—Jaundice—Doxorubicin—thyroid cancer	0.000558	0.00171	CcSEcCtD
Captopril—Rhinitis—Epirubicin—thyroid cancer	0.000557	0.00171	CcSEcCtD
Captopril—Hepatitis—Epirubicin—thyroid cancer	0.000555	0.00171	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000553	0.00233	CbGpPWpGaD
Captopril—Pharyngitis—Epirubicin—thyroid cancer	0.000551	0.00169	CcSEcCtD
Captopril—ABCB1—lymph node—thyroid cancer	0.00055	0.00352	CbGeAlD
Captopril—LTA4H—Metabolism—SLC5A5—thyroid cancer	0.000548	0.00231	CbGpPWpGaD
Captopril—Agranulocytosis—Doxorubicin—thyroid cancer	0.000534	0.00164	CcSEcCtD
Captopril—Erythema multiforme—Epirubicin—thyroid cancer	0.000525	0.00161	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000524	0.00221	CbGpPWpGaD
Captopril—Flushing—Epirubicin—thyroid cancer	0.000515	0.00158	CcSEcCtD
Captopril—Rhinitis—Doxorubicin—thyroid cancer	0.000515	0.00158	CcSEcCtD
Captopril—F2—GPCR downstream signaling—CALCB—thyroid cancer	0.000514	0.00216	CbGpPWpGaD
Captopril—Hepatitis—Doxorubicin—thyroid cancer	0.000514	0.00158	CcSEcCtD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000514	0.00216	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—CDK1—thyroid cancer	0.000513	0.00216	CbGpPWpGaD
Captopril—Pharyngitis—Doxorubicin—thyroid cancer	0.00051	0.00157	CcSEcCtD
Captopril—MMP2—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000508	0.00214	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000506	0.00213	CbGpPWpGaD
Captopril—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000494	0.00208	CbGpPWpGaD
Captopril—Alopecia—Epirubicin—thyroid cancer	0.000491	0.00151	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000489	0.00206	CbGpPWpGaD
Captopril—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000489	0.00206	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—PTGS2—thyroid cancer	0.000488	0.00206	CbGpPWpGaD
Captopril—Erythema multiforme—Doxorubicin—thyroid cancer	0.000486	0.00149	CcSEcCtD
Captopril—F2—Platelet Aggregation (Plug Formation)—AKT1—thyroid cancer	0.000479	0.00202	CbGpPWpGaD
Captopril—Flushing—Doxorubicin—thyroid cancer	0.000477	0.00146	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000477	0.00201	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—RXRA—thyroid cancer	0.000477	0.00201	CbGpPWpGaD
Captopril—Tension—Epirubicin—thyroid cancer	0.000474	0.00146	CcSEcCtD
Captopril—Dysgeusia—Epirubicin—thyroid cancer	0.000473	0.00145	CcSEcCtD
Captopril—MMP9—Axon guidance—CDK1—thyroid cancer	0.000472	0.00199	CbGpPWpGaD
Captopril—Nervousness—Epirubicin—thyroid cancer	0.000469	0.00144	CcSEcCtD
Captopril—F2—Signaling by GPCR—CALCB—thyroid cancer	0.000467	0.00197	CbGpPWpGaD
Captopril—LTA4H—Metabolism—RXRA—thyroid cancer	0.00046	0.00194	CbGpPWpGaD
Captopril—MMP9—FGF signaling pathway—AKT1—thyroid cancer	0.000458	0.00193	CbGpPWpGaD
Captopril—Vision blurred—Epirubicin—thyroid cancer	0.000456	0.0014	CcSEcCtD
Captopril—Alopecia—Doxorubicin—thyroid cancer	0.000454	0.00139	CcSEcCtD
Captopril—MMP9—LPA receptor mediated events—HRAS—thyroid cancer	0.000453	0.00191	CbGpPWpGaD
Captopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000451	0.0019	CbGpPWpGaD
Captopril—Ill-defined disorder—Epirubicin—thyroid cancer	0.000449	0.00138	CcSEcCtD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000448	0.00189	CbGpPWpGaD
Captopril—Anaemia—Epirubicin—thyroid cancer	0.000447	0.00137	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—TP53—thyroid cancer	0.000441	0.00186	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—CCND1—thyroid cancer	0.000441	0.00186	CbGpPWpGaD
Captopril—Tension—Doxorubicin—thyroid cancer	0.000439	0.00135	CcSEcCtD
Captopril—Dysgeusia—Doxorubicin—thyroid cancer	0.000438	0.00135	CcSEcCtD
Captopril—Malaise—Epirubicin—thyroid cancer	0.000436	0.00134	CcSEcCtD
Captopril—Nervousness—Doxorubicin—thyroid cancer	0.000434	0.00133	CcSEcCtD
Captopril—Syncope—Epirubicin—thyroid cancer	0.000433	0.00133	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00043	0.00181	CbGpPWpGaD
Captopril—Palpitations—Epirubicin—thyroid cancer	0.000427	0.00131	CcSEcCtD
Captopril—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000427	0.0018	CbGpPWpGaD
Captopril—Loss of consciousness—Epirubicin—thyroid cancer	0.000425	0.0013	CcSEcCtD
Captopril—Cough—Epirubicin—thyroid cancer	0.000422	0.0013	CcSEcCtD
Captopril—Vision blurred—Doxorubicin—thyroid cancer	0.000422	0.00129	CcSEcCtD
Captopril—F2—GPCR ligand binding—TSHR—thyroid cancer	0.000421	0.00177	CbGpPWpGaD
Captopril—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000417	0.00176	CbGpPWpGaD
Captopril—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000415	0.00127	CcSEcCtD
Captopril—Anaemia—Doxorubicin—thyroid cancer	0.000413	0.00127	CcSEcCtD
Captopril—Myalgia—Epirubicin—thyroid cancer	0.000412	0.00126	CcSEcCtD
Captopril—Chest pain—Epirubicin—thyroid cancer	0.000412	0.00126	CcSEcCtD
Captopril—Arthralgia—Epirubicin—thyroid cancer	0.000412	0.00126	CcSEcCtD
Captopril—Discomfort—Epirubicin—thyroid cancer	0.000407	0.00125	CcSEcCtD
Captopril—Malaise—Doxorubicin—thyroid cancer	0.000403	0.00124	CcSEcCtD
Captopril—Dry mouth—Epirubicin—thyroid cancer	0.000402	0.00124	CcSEcCtD
Captopril—Syncope—Doxorubicin—thyroid cancer	0.000401	0.00123	CcSEcCtD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—thyroid cancer	0.0004	0.00169	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—AKT1—thyroid cancer	0.0004	0.00169	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—AKT1—thyroid cancer	0.0004	0.00169	CbGpPWpGaD
Captopril—Confusional state—Epirubicin—thyroid cancer	0.000398	0.00122	CcSEcCtD
Captopril—Palpitations—Doxorubicin—thyroid cancer	0.000395	0.00121	CcSEcCtD
Captopril—Anaphylactic shock—Epirubicin—thyroid cancer	0.000395	0.00121	CcSEcCtD
Captopril—Loss of consciousness—Doxorubicin—thyroid cancer	0.000393	0.00121	CcSEcCtD
Captopril—MMP9—AGE/RAGE pathway—AKT1—thyroid cancer	0.00039	0.00164	CbGpPWpGaD
Captopril—Cough—Doxorubicin—thyroid cancer	0.00039	0.0012	CcSEcCtD
Captopril—Shock—Epirubicin—thyroid cancer	0.000388	0.00119	CcSEcCtD
Captopril—F2—Regulation of Actin Cytoskeleton—BRAF—thyroid cancer	0.000387	0.00163	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—thyroid cancer	0.000386	0.00163	CbGpPWpGaD
Captopril—Thrombocytopenia—Epirubicin—thyroid cancer	0.000386	0.00119	CcSEcCtD
Captopril—Tachycardia—Epirubicin—thyroid cancer	0.000385	0.00118	CcSEcCtD
Captopril—Myalgia—Doxorubicin—thyroid cancer	0.000381	0.00117	CcSEcCtD
Captopril—Chest pain—Doxorubicin—thyroid cancer	0.000381	0.00117	CcSEcCtD
Captopril—Arthralgia—Doxorubicin—thyroid cancer	0.000381	0.00117	CcSEcCtD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—thyroid cancer	0.000376	0.00159	CbGpPWpGaD
Captopril—Discomfort—Doxorubicin—thyroid cancer	0.000376	0.00116	CcSEcCtD
Captopril—Anorexia—Epirubicin—thyroid cancer	0.000376	0.00115	CcSEcCtD
Captopril—Dry mouth—Doxorubicin—thyroid cancer	0.000372	0.00114	CcSEcCtD
Captopril—F2—Hemostasis—PRKAR1A—thyroid cancer	0.00037	0.00156	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—PTEN—thyroid cancer	0.000369	0.00156	CbGpPWpGaD
Captopril—Hypotension—Epirubicin—thyroid cancer	0.000369	0.00113	CcSEcCtD
Captopril—Confusional state—Doxorubicin—thyroid cancer	0.000368	0.00113	CcSEcCtD
Captopril—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000366	0.00154	CbGpPWpGaD
Captopril—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000365	0.00112	CcSEcCtD
Captopril—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000359	0.0011	CcSEcCtD
Captopril—Shock—Doxorubicin—thyroid cancer	0.000359	0.0011	CcSEcCtD
Captopril—F2—GPCR ligand binding—PTCH1—thyroid cancer	0.000358	0.00151	CbGpPWpGaD
Captopril—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000357	0.0011	CcSEcCtD
Captopril—F2—Folate Metabolism—TP53—thyroid cancer	0.000357	0.0015	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CALCB—thyroid cancer	0.000357	0.0015	CbGpPWpGaD
Captopril—Insomnia—Epirubicin—thyroid cancer	0.000357	0.0011	CcSEcCtD
Captopril—Tachycardia—Doxorubicin—thyroid cancer	0.000356	0.00109	CcSEcCtD
Captopril—Paraesthesia—Epirubicin—thyroid cancer	0.000354	0.00109	CcSEcCtD
Captopril—Dyspnoea—Epirubicin—thyroid cancer	0.000352	0.00108	CcSEcCtD
Captopril—Somnolence—Epirubicin—thyroid cancer	0.000351	0.00108	CcSEcCtD
Captopril—Anorexia—Doxorubicin—thyroid cancer	0.000348	0.00107	CcSEcCtD
Captopril—Dyspepsia—Epirubicin—thyroid cancer	0.000347	0.00107	CcSEcCtD
Captopril—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000346	0.00146	CbGpPWpGaD
Captopril—Decreased appetite—Epirubicin—thyroid cancer	0.000343	0.00105	CcSEcCtD
Captopril—Hypotension—Doxorubicin—thyroid cancer	0.000341	0.00105	CcSEcCtD
Captopril—Fatigue—Epirubicin—thyroid cancer	0.00034	0.00104	CcSEcCtD
Captopril—MMP9—Signaling Pathways—TRIM33—thyroid cancer	0.000338	0.00143	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—NRAS—thyroid cancer	0.000337	0.00142	CbGpPWpGaD
Captopril—Constipation—Epirubicin—thyroid cancer	0.000337	0.00104	CcSEcCtD
Captopril—MMP9—Developmental Biology—CDK1—thyroid cancer	0.000337	0.00142	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000335	0.00141	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000335	0.00141	CbGpPWpGaD
Captopril—MMP9—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000333	0.0014	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000333	0.00102	CcSEcCtD
Captopril—Insomnia—Doxorubicin—thyroid cancer	0.00033	0.00101	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00033	0.00139	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—NRAS—thyroid cancer	0.000329	0.00139	CbGpPWpGaD
Captopril—Paraesthesia—Doxorubicin—thyroid cancer	0.000328	0.00101	CcSEcCtD
Captopril—F2—GPCR ligand binding—SST—thyroid cancer	0.000327	0.00138	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000326	0.00137	CbGpPWpGaD
Captopril—Dyspnoea—Doxorubicin—thyroid cancer	0.000325	0.000999	CcSEcCtD
Captopril—Feeling abnormal—Epirubicin—thyroid cancer	0.000325	0.000998	CcSEcCtD
Captopril—Somnolence—Doxorubicin—thyroid cancer	0.000325	0.000997	CcSEcCtD
Captopril—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000323	0.000991	CcSEcCtD
Captopril—MMP9—CXCR4-mediated signaling events—AKT1—thyroid cancer	0.000322	0.00136	CbGpPWpGaD
Captopril—Dyspepsia—Doxorubicin—thyroid cancer	0.000321	0.000987	CcSEcCtD
Captopril—Decreased appetite—Doxorubicin—thyroid cancer	0.000317	0.000974	CcSEcCtD
Captopril—F2—GPCR ligand binding—CALCA—thyroid cancer	0.000315	0.00133	CbGpPWpGaD
Captopril—Fatigue—Doxorubicin—thyroid cancer	0.000315	0.000966	CcSEcCtD
Captopril—MMP9—Developmental Biology—RXRA—thyroid cancer	0.000313	0.00132	CbGpPWpGaD
Captopril—Constipation—Doxorubicin—thyroid cancer	0.000312	0.000959	CcSEcCtD
Captopril—Abdominal pain—Epirubicin—thyroid cancer	0.000312	0.000958	CcSEcCtD
Captopril—Body temperature increased—Epirubicin—thyroid cancer	0.000312	0.000958	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000312	0.00131	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—PPARG—thyroid cancer	0.000301	0.00127	CbGpPWpGaD
Captopril—Feeling abnormal—Doxorubicin—thyroid cancer	0.000301	0.000924	CcSEcCtD
Captopril—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000298	0.000917	CcSEcCtD
Captopril—LTA4H—Metabolism—PPARG—thyroid cancer	0.000291	0.00122	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TP53—thyroid cancer	0.000291	0.00122	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—KRAS—thyroid cancer	0.00029	0.00122	CbGpPWpGaD
Captopril—Body temperature increased—Doxorubicin—thyroid cancer	0.000289	0.000886	CcSEcCtD
Captopril—Abdominal pain—Doxorubicin—thyroid cancer	0.000289	0.000886	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—KRAS—thyroid cancer	0.000283	0.00119	CbGpPWpGaD
Captopril—Asthenia—Epirubicin—thyroid cancer	0.000283	0.000869	CcSEcCtD
Captopril—Pruritus—Epirubicin—thyroid cancer	0.000279	0.000857	CcSEcCtD
Captopril—F2—Signaling Pathways—CALCB—thyroid cancer	0.000276	0.00116	CbGpPWpGaD
Captopril—Diarrhoea—Epirubicin—thyroid cancer	0.00027	0.000829	CcSEcCtD
Captopril—Asthenia—Doxorubicin—thyroid cancer	0.000262	0.000804	CcSEcCtD
Captopril—F2—Signaling Pathways—TRIM33—thyroid cancer	0.000261	0.0011	CbGpPWpGaD
Captopril—Dizziness—Epirubicin—thyroid cancer	0.000261	0.000801	CcSEcCtD
Captopril—Pruritus—Doxorubicin—thyroid cancer	0.000258	0.000793	CcSEcCtD
Captopril—MMP2—Axon guidance—NRAS—thyroid cancer	0.000258	0.00109	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000254	0.00107	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000254	0.00107	CbGpPWpGaD
Captopril—Vomiting—Epirubicin—thyroid cancer	0.000251	0.00077	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000251	0.00106	CbGpPWpGaD
Captopril—Diarrhoea—Doxorubicin—thyroid cancer	0.00025	0.000767	CcSEcCtD
Captopril—Rash—Epirubicin—thyroid cancer	0.000249	0.000764	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000249	0.00105	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	0.000249	0.00105	CbGpPWpGaD
Captopril—Dermatitis—Epirubicin—thyroid cancer	0.000249	0.000763	CcSEcCtD
Captopril—Headache—Epirubicin—thyroid cancer	0.000247	0.000759	CcSEcCtD
Captopril—F2—Cell surface interactions at the vascular wall—HRAS—thyroid cancer	0.000247	0.00104	CbGpPWpGaD
Captopril—F2—Hemostasis—IFNA2—thyroid cancer	0.000245	0.00103	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000245	0.00103	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—NRAS—thyroid cancer	0.000243	0.00102	CbGpPWpGaD
Captopril—Dizziness—Doxorubicin—thyroid cancer	0.000241	0.000741	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—HRAS—thyroid cancer	0.000241	0.00101	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—TSHR—thyroid cancer	0.000238	0.001	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000237	0.000997	CbGpPWpGaD
Captopril—Nausea—Epirubicin—thyroid cancer	0.000234	0.00072	CcSEcCtD
Captopril—Vomiting—Doxorubicin—thyroid cancer	0.000232	0.000713	CcSEcCtD
Captopril—Rash—Doxorubicin—thyroid cancer	0.00023	0.000707	CcSEcCtD
Captopril—Dermatitis—Doxorubicin—thyroid cancer	0.00023	0.000706	CcSEcCtD
Captopril—LTA4H—Metabolism—PTGS2—thyroid cancer	0.000229	0.000963	CbGpPWpGaD
Captopril—Headache—Doxorubicin—thyroid cancer	0.000229	0.000702	CcSEcCtD
Captopril—MMP9—Signaling Pathways—TCF7L1—thyroid cancer	0.000226	0.000951	CbGpPWpGaD
Captopril—MMP2—Axon guidance—KRAS—thyroid cancer	0.000222	0.000936	CbGpPWpGaD
Captopril—Nausea—Doxorubicin—thyroid cancer	0.000217	0.000666	CcSEcCtD
Captopril—F2—Signaling by GPCR—TSHR—thyroid cancer	0.000216	0.00091	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—AKT1—thyroid cancer	0.000213	0.000896	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000213	0.000895	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000211	0.000888	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—KRAS—thyroid cancer	0.000209	0.000882	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PTEN—thyroid cancer	0.000199	0.00084	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—PPARG—thyroid cancer	0.000197	0.000831	CbGpPWpGaD
Captopril—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00019	0.000802	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000189	0.000797	CbGpPWpGaD
Captopril—MMP2—Axon guidance—HRAS—thyroid cancer	0.000189	0.000795	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000186	0.000784	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—SST—thyroid cancer	0.000185	0.000779	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—NRAS—thyroid cancer	0.000184	0.000776	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000184	0.000775	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTCH1—thyroid cancer	0.000184	0.000774	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000181	0.000764	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000179	0.000756	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CALCA—thyroid cancer	0.000178	0.00075	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TCF7L1—thyroid cancer	0.000174	0.000734	CbGpPWpGaD
Captopril—MMP9—Axon guidance—NRAS—thyroid cancer	0.000169	0.000713	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—SST—thyroid cancer	0.000168	0.000708	CbGpPWpGaD
Captopril—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000165	0.000697	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TSHR—thyroid cancer	0.000165	0.000696	CbGpPWpGaD
Captopril—ALB—Metabolism—MINPP1—thyroid cancer	0.000164	0.000689	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PRKAR1A—thyroid cancer	0.000163	0.000685	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CALCA—thyroid cancer	0.000162	0.000681	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—KRAS—thyroid cancer	0.000158	0.000668	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000156	0.000659	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000156	0.000658	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MEN1—thyroid cancer	0.000155	0.000655	CbGpPWpGaD
Captopril—ALB—Hemostasis—PRKAR1A—thyroid cancer	0.000147	0.000619	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CDK1—thyroid cancer	0.000146	0.000617	CbGpPWpGaD
Captopril—MMP9—Axon guidance—KRAS—thyroid cancer	0.000146	0.000614	CbGpPWpGaD
Captopril—ABCB1—Metabolism—MINPP1—thyroid cancer	0.000143	0.000604	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—thyroid cancer	0.000142	0.000597	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTCH1—thyroid cancer	0.000141	0.000592	CbGpPWpGaD
Captopril—ALB—Metabolism—NDUFA13—thyroid cancer	0.000139	0.000586	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000135	0.000569	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—HRAS—thyroid cancer	0.000135	0.000568	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000133	0.000559	CbGpPWpGaD
Captopril—ALB—Metabolism—CHST14—thyroid cancer	0.000131	0.000551	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	0.000129	0.000545	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000129	0.000545	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SST—thyroid cancer	0.000129	0.000541	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TSHR—thyroid cancer	0.000128	0.000538	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000127	0.000536	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000126	0.000529	CbGpPWpGaD
Captopril—MMP9—Axon guidance—HRAS—thyroid cancer	0.000124	0.000522	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CALCA—thyroid cancer	0.000124	0.000521	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000122	0.000513	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—NRAS—thyroid cancer	0.000121	0.000509	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MEN1—thyroid cancer	0.00012	0.000505	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—AKT1—thyroid cancer	0.000119	0.000501	CbGpPWpGaD
Captopril—LTA4H—Metabolism—AKT1—thyroid cancer	0.000115	0.000484	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000115	0.000484	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000115	0.000483	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CHST14—thyroid cancer	0.000115	0.000483	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000113	0.000477	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000113	0.000477	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CDK1—thyroid cancer	0.000112	0.000472	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000111	0.000469	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTCH1—thyroid cancer	0.000109	0.000457	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000108	0.000455	CbGpPWpGaD
Captopril—ALB—Metabolism—HPGD—thyroid cancer	0.000105	0.000444	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000105	0.000442	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—KRAS—thyroid cancer	0.000104	0.000438	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SST—thyroid cancer	9.92e-05	0.000418	CbGpPWpGaD
Captopril—ALB—Hemostasis—IFNA2—thyroid cancer	9.73e-05	0.00041	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.68e-05	0.000408	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CALCA—thyroid cancer	9.55e-05	0.000402	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HPGD—thyroid cancer	9.24e-05	0.000389	CbGpPWpGaD
Captopril—F2—Hemostasis—NRAS—thyroid cancer	9.15e-05	0.000385	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NRG1—thyroid cancer	8.99e-05	0.000379	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	8.91e-05	0.000375	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—HRAS—thyroid cancer	8.84e-05	0.000372	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HPGD—thyroid cancer	8.71e-05	0.000367	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CDK1—thyroid cancer	8.65e-05	0.000364	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.55e-05	0.00036	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.48e-05	0.000357	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.13e-05	0.000343	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TERT—thyroid cancer	8.07e-05	0.00034	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.05e-05	0.000339	CbGpPWpGaD
Captopril—F2—Hemostasis—KRAS—thyroid cancer	7.87e-05	0.000332	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—AKT1—thyroid cancer	7.8e-05	0.000329	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.77e-05	0.000327	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HIF1A—thyroid cancer	7.72e-05	0.000325	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.13e-05	0.0003	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—thyroid cancer	7e-05	0.000295	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NRG1—thyroid cancer	6.94e-05	0.000292	CbGpPWpGaD
Captopril—F2—Hemostasis—HRAS—thyroid cancer	6.69e-05	0.000282	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—BRAF—thyroid cancer	6.39e-05	0.000269	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TERT—thyroid cancer	6.23e-05	0.000263	CbGpPWpGaD
Captopril—ALB—Metabolism—TPR—thyroid cancer	6.06e-05	0.000255	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.97e-05	0.000251	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HIF1A—thyroid cancer	5.96e-05	0.000251	CbGpPWpGaD
Captopril—ALB—Metabolism—PRKAR1A—thyroid cancer	5.96e-05	0.000251	CbGpPWpGaD
Captopril—F2—Hemostasis—AKT1—thyroid cancer	5.91e-05	0.000249	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.4e-05	0.000227	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TPR—thyroid cancer	5.31e-05	0.000224	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.3e-05	0.000223	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—NRAS—thyroid cancer	5.25e-05	0.000221	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PRKAR1A—thyroid cancer	5.22e-05	0.00022	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TPR—thyroid cancer	5e-05	0.000211	CbGpPWpGaD
Captopril—F2—Signaling Pathways—BRAF—thyroid cancer	4.94e-05	0.000208	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	4.92e-05	0.000207	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCND1—thyroid cancer	4.67e-05	0.000197	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	4.55e-05	0.000192	CbGpPWpGaD
Captopril—ALB—Metabolism—SLC5A5—thyroid cancer	4.53e-05	0.000191	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—KRAS—thyroid cancer	4.52e-05	0.00019	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTEN—thyroid cancer	4.5e-05	0.00019	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.48e-05	0.000189	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.25e-05	0.000179	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NRAS—thyroid cancer	4.02e-05	0.000169	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SLC5A5—thyroid cancer	3.97e-05	0.000167	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HRAS—thyroid cancer	3.84e-05	0.000162	CbGpPWpGaD
Captopril—ALB—Metabolism—RXRA—thyroid cancer	3.81e-05	0.00016	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SLC5A5—thyroid cancer	3.74e-05	0.000158	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—AKT1—thyroid cancer	3.74e-05	0.000157	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.7e-05	0.000156	CbGpPWpGaD
Captopril—ALB—Hemostasis—NRAS—thyroid cancer	3.63e-05	0.000153	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCND1—thyroid cancer	3.6e-05	0.000152	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTEN—thyroid cancer	3.48e-05	0.000146	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KRAS—thyroid cancer	3.46e-05	0.000146	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—AKT1—thyroid cancer	3.39e-05	0.000143	CbGpPWpGaD
Captopril—ABCB1—Metabolism—RXRA—thyroid cancer	3.34e-05	0.000141	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—RXRA—thyroid cancer	3.14e-05	0.000132	CbGpPWpGaD
Captopril—ALB—Hemostasis—KRAS—thyroid cancer	3.12e-05	0.000132	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NRAS—thyroid cancer	3.1e-05	0.000131	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—thyroid cancer	3.07e-05	0.000129	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HRAS—thyroid cancer	2.94e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—thyroid cancer	2.78e-05	0.000117	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KRAS—thyroid cancer	2.67e-05	0.000112	CbGpPWpGaD
Captopril—ALB—Hemostasis—HRAS—thyroid cancer	2.66e-05	0.000112	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—AKT1—thyroid cancer	2.6e-05	0.000109	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARG—thyroid cancer	2.4e-05	0.000101	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—thyroid cancer	2.37e-05	9.99e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—AKT1—thyroid cancer	2.35e-05	9.88e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HRAS—thyroid cancer	2.27e-05	9.56e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARG—thyroid cancer	2.11e-05	8.88e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—AKT1—thyroid cancer	2e-05	8.44e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARG—thyroid cancer	1.99e-05	8.36e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTGS2—thyroid cancer	1.89e-05	7.97e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTGS2—thyroid cancer	1.66e-05	6.98e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTEN—thyroid cancer	1.65e-05	6.95e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.56e-05	6.58e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTEN—thyroid cancer	1.45e-05	6.09e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTEN—thyroid cancer	1.36e-05	5.74e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—AKT1—thyroid cancer	9.51e-06	4.01e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—AKT1—thyroid cancer	8.33e-06	3.51e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—AKT1—thyroid cancer	7.85e-06	3.31e-05	CbGpPWpGaD
